OGEN ORAGENICS INC Investments/Divestments 8-K Filing 2024 - Drug Development Update Oragenics Inc announced an update on its drug development program for its lead drug candidate, ONP-002, stating that it does not cause cardiotoxicity.Get access to all SEC 8-K filings of the ORAGENICS INC